NCT06564324 2026-04-13
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.
Phase 3 Recruiting
Nuvation Bio Inc.
Canadian Cancer Trials Group
M.D. Anderson Cancer Center
IDEAYA Biosciences